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The  DNA  repair  gene  O6-methylguanine-DNA  methyltransferase  (MGMT)  allows  efﬁcient  in vivo  enrich-
ment  of transduced  hematopoietic  stem  cells  (HSC).  Thus,  linking  this  selection  strategy  to  therapeutic
gene  expression  offers  the potential  to  reconstitute  diseased  hematopoietic  tissue  with  gene-corrected
cells.  However,  different  dual-gene  expression  vector  strategies  are  limited  by poor  expression  of  one
or both  transgenes.  To  evaluate  different  co-expression  strategies  in the context  of  MGMT-mediated
HSC  enrichment,  we  compared  selection  and  expression  efﬁcacies  in cells  cotransduced  with  separate
single-gene  MGMT  and  GFP  lentivectors  to those  obtained  with  dual-gene  vectors  employing  either
encephalomyocarditis  virus  (EMCV)  internal  ribosome  entry  site  (IRES)  or foot  and mouth  disease  virus
(FMDV)  2A  elements  for co-expression  strategies.  Each  strategy  was  evaluated  in vitro and  in vivo using
equivalent  multiplicities  of  infection  (MOI)  to  transduce  5-ﬂuorouracil  (5-FU)  or Lin−Sca-1+c-kit+ (LSK)-
enriched  murine  bone  marrow  cells (BMCs).  The  highest  dual-gene  expression  (MGMT+GFP+)  percentages
were  obtained  with  the  FMDV-2A  dual-gene  vector,  but  half  of the  resulting  gene  products  existed  as
fusion  proteins.  Following  selection,  dual-gene  expression  percentages  in single-gene  vector  cotrans-
duced  and dual-gene  vector  transduced  populations  were  similar.  Equivalent  MGMT  expression  levels
were obtained  with  each  strategy,  but  GFP expression  levels  derived  from  the  IRES  dual-gene  vector  were
signiﬁcantly  lower.  In mice,  vector-insertion  averages  were  similar  among  cells  enriched  after  dual-gene
vectors  and  those  cotransduced  with single-gene  vectors.  These  data  demonstrate  the  limitations  and
advantages  of  each  strategy  in  the  context  of  MGMT-mediated  selection,  and  may  provide  insights  into
vector  design  with  respect  to  a particular  therapeutic  gene  or  hematologic  defect.
ublis©  2014  The  Authors.  P
. IntroductionA number of drug resistance genes have been evaluated for
elective enrichment of transduced stem cells in vivo (Corey et al.,
990; Allay et al., 1997, 1998; Sorrentino et al., 1992). However, the
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168-1702/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unhed  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
most robust stem cell selection has been achieved using speciﬁc
point mutants of MGMT  (Davis et al., 2000; Bowman et al., 2003).
MGMT  repairs O6-methylguanine and O6-chloroethylguanine DNA
lesions induced by chemotherapeutics such as Temozolomide and
1,3-Bis(2-Chloroethyl)-Nitrosourea (BCNU), respectively. MGMT
point mutants, including P140K and G156A, are resistant to the
wild-type MGMT  inhibitor, O6-benzylguanine (BG), but retain wild-
type DNA repair activity (Crone and Pegg, 1993; Crone et al.,
1994; Loktionova and Pegg, 1996). Thus, the endogenous MGMT
in untransduced BMCs is inactivated by BG treatment, sensitizing
these cells to alkylating agent damage, while mutant MGMT-
transduced cells are protected from the combined BG and alkylating
agent insult (Reese et al., 1996). With sequential treatments, this
differential sensitivity allows transduced stem cells to survive and
repopulate the hematopoietic compartment (Davis et al., 2000;
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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owman et al., 2003; Pollok et al., 2003; Zielske et al., 2003; Beard
t al., 2009, 2010). Therefore, dual-gene vectors that couple MGMT-
ediated stem cell selection to therapeutic gene expression should
llow diseased hematopoietic tissues to be reconstituted with func-
ional, gene corrected cells. The feasibility of this approach has
een demonstrated in animal models of -thalassemia (Persons
t al., 2003; Falahati et al., 2012), protoporphyria (Richard et al.,
004), and HIV/AIDS (Trobridge et al., 2009). However, higher MOIs
re often required to compensate for the lower expression levels
btained with dual-gene vectors.
Several methods have been devised to co-express two genes
rom the same viral vector. Two of the most common strategies
tilize either an IRES (Morgan et al., 1992; Sugimoto et al., 1994),
r ribosome slippage (de Felipe et al., 1999; Klump et al., 2001)
equences for dual-gene expression. IRES elements form secondary
NA structures that act to initiate translation in a cap-independent
ashion. Therefore, these elements can be used to express additional
enes from the same transcript. Many endogenous and exogenous
RES sequences have been identiﬁed, but the sequence derived from
he EMCV IRES is one of the most thoroughly characterized and
idely used IRES elements in dual-gene expression vectors (Jang
nd Wimmer, 1990; Davies and Kaufman, 1992). IRES-mediated
ranslation efﬁciency is typically reduced by 20–50%, compared to
he cap-dependent mechanism (Mizuguchi et al., 2000; Yu et al.,
003). In addition, IRES activity can be inﬂuenced by the speciﬁc
enes used, and their position with respect to the IRES sequence
Davies and Kaufman, 1992; Hennecke et al., 2001).
Whereas IRES elements function to initiate translation,
ibosome-slippage sites, such as the FMDV 2A element, are active
uring translation. The short nucleotide sequence encoding FMDV-
A is positioned between two genes, the ﬁrst of which has the stop
odon removed. Thus, both genes and the 2A element are joined
s one open reading frame. After the ﬁrst gene and 2A sequence
re translated, cis-acting hydrolase activity within the 2A residues
auses the ribosome to “skip” the last peptide bond in 2A. Thus,
epending on the 2A nucleotide sequence employed the ﬁrst gene
roduct is released with 17–23 residues (with up to 32 residues
emonstrating increased efﬁciency (Donnelly et al., 2001)) from the
A element fused to its C-terminus. The ribosome then continues
ranslating the second gene product, which contains an N-terminal
roline from the 2A sequence (de Felipe, in press). Like IRES ele-
ents, the efﬁciency of ribosome slippage sequences appears to
e sensitive to the speciﬁc gene combinations used (Milsom et al.,
004; Chan et al., 2011). Further, the activity of the ﬁrst gene prod-
ct can be perturbed by the 2A residues that remain fused to its
-terminus (Lengler et al., 2005).
Herein, we evaluated the use of two separate single-gene
entiviral vectors (one encoding MGMT-P140K and the other
xpressing GFP) to cotransduce and selectively enrich dual-gene
xpressing hematopoietic populations in vivo. Cotransduction was
hen compared to dual-gene vectors that utilize the EMCV-IRES
r FMDV-2A elements for co-expression. Comparisons were made
ased on enrichment of dual-gene expressing cells, individual gene
xpression levels, and total vector insertion averages. Although
ach strategy may  be more or less efﬁcient, depending on the
arget cells and the speciﬁc genes used, this study demonstrates
he advantages and limitations of each strategy in the context of
GMT-mediated hematopoietic progenitor cell enrichment.
. Materials and methods.1. Vectors
The self-inactivating lentiviral luciferase (Luc) vector, pCSO-
re-cppt-MCU3-LUC, was obtained from Donald Kohn (Universityh 196 (2015) 170–180 171
of California, Los Angeles, CA). It contains the MND  (myeloproli-
ferative sarcoma virus enhancer, negative control region deleted,
dl587rev primer-binding site substituted) promoter/enhancer
sequence, the rev response element (RRE), and the central
polypurine tract/central termination sequence (cPPT/CTS). Luc
was removed by partial restriction with NcoI and EcoRI and
replaced with a multiple cloning site linker. The MGMT-P140K
and enhanced GFP coding sequences were separately inserted
into the NcoI site (closest to the MND  promoter) and a unique
BamHI site. These constructs were then restricted at unique
BamHI and EcoRI sites for insertion of the woodchuck hepatitis
virus posttranscriptional regulatory element (wPRE; provided by
Thomas Hope, Northwestern University, Chicago, IL) (Zufferey
et al., 1999; Hlavaty et al., 2005) to generate the pMND-MGMT
and pMND-GFP single-gene vectors. The EMCV IRES element was
obtained from the pCITE-2a vector (Clontech, Mountain View,
CA). The IRES sequence was  deleted from pCITE-2a by partial
PvuII and MscI restriction and the resulting vector fragment was
religated. 5′-NotI and 3′-EcoRI sites were added onto the deleted
IRES sequence by PCR and the restricted PCR product was  added
back to the IRES-deleted pCITE-2a vector, generating an IRES vector
with both 5′ and 3′ multiple cloning sites, termed pSOB. GFP was
cloned into pSOB using NcoI and BamHI to position the GFP start
codon at the site reported to maximize IRES-mediated translation
(Davies and Kaufman, 1992). The IRES-GFP cassette was then
removed and placed 70 nt downstream of MGMT  using a unique
NotI  site in pMND-MGMT, generating pMND-MIG. The FMDV-2A
sequence was  generated from oligos using overlap extension
PCR. An MGMT-2A PCR fragment was generated using the oligos,
MGMT-FOR (5′-GTGAGCAGGGTCTGCACGAA-3′) and MGMT-2A (5′-
CTGCCAACTTGAGCAGGTCAAAGCTCAAAAGCTGTTTCACCGGTGCG-
TTTCGGCCAGCAG-3′). A separate 2A-GFP fragment was gener-
ated using the oligos 2A-GFP (5′-GGCAGGGGACGTCGAGTCCAA-
CCCTGGGCC TATGGTGAGCAAGGGCGA-3′) and GFP-REV (5′-
CTAGAGCGGCCGCTTTACTTGTACAGCTCGTCC-3′). The resulting
MGMT-2A and 2A-GFP fragments were annealed, extended, and
ampliﬁed with the MGMT-FOR and GFP-REV oligos. The resulting
fragment was cloned into pMND-MIG using a unique SﬁI  site
within MGMT  and a NotI site 3′ of GFP, generating pMND-MAG. All
constructs were veriﬁed by sequencing.
2.2. Virus preparation and transductions
Virus was generated as previously described (Roth et al., 2012).
In brief, 293T cells (ATCC, Manassas, VA) were transfected with the
VSV-G pseudotyping vector (pMD.G) (Naldini et al., 1996), the pack-
aging vector (pCMVR8.91) (Zufferey et al., 1997), and the pMND
transducing vectors at a 3:1:3 mass ratio, using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s proto-
col. At 24–48 h after transfection, virus was harvested in Dulbecco’s
modiﬁed Eagle medium (DMEM; Cellgro, Manassas, VA) contain-
ing 10% heat-inactivated (HI)-fetal bovine serum (FBS) (Cellgro)
and 2 mM GlutaMAX (Invitrogen); then ﬁltered through 0.45 m
syringe ﬁlter units (Millipore, Billerica, MA); and ﬁnally stored at
–80 ◦C. Expression titers were determined on K562 cells (ATCC)
using virus dilutions that resulted in less than 10% transduction.
Titers ranged from 0.5 to 3.0 × 107 expression units (EU)/mL. Virus
preps used for cotransductions were premixed at the speciﬁed MOI
ratios prior to the addition of cells. K562 cells were transduced
in Iscove’s medium (Cellgro) containing 10% HI-FBS, 2 mM Gluta-
MAX, and 8 g/mL polybrene (Sigma, St. Louis, MO). BMCs (isolated
from 5-FU treated animals as previously described (Roth et al.,
2012)) and sorted Lin−Sca-1+c-kit+ (LSK) cell populations (iso-
lated as previously described (Reese et al., 2003)) were transduced
for 12 h in alpha-MEM containing 20% Hi-FBS, 2 mM GlutaMAX,
6 g/mL polybrene, in the presence of murine IL-3 (20 ng/mL),
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urine IL-6 (50 ng/mL), and rat SCF (50 ng/mL) (R&D Systems
nc., Minneapolis, MN). MOIs deﬁned for mouse cell transduc-
ions were derived from the expression titers established in K562
ells.
.3. Animals and transplants
Transduced LSK cells (as above) were transplanted immediately
fter transduction. Six-week-old C57BL/6J recipient mice (Jackson
aboratories, Bar Harbor, ME)  were lethally irradiated with 8.5 Gy
sing a Cs137 source and transplanted with 103 cells from each
ransduction culture, along with 2 × 106 Lin+ cells (for hematopoi-
tic support) per mouse. The animals were sacriﬁced at 17 weeks
or expression and vector insertion number analysis in BMCs and
FU, respectively.
Fold-enrichment was calculated as follows: [(% GFP+ BMCs at 17
eeks) × (3 × 108 total BMCs in reconstituted mouse)] ÷ [(% GFP+
ransplanted LSK cells) × (total # transplanted LSK cells)]. Analysis
f vector insertions is described below.
.4. Drug selection
BG was synthesized by Robert Moschel at the Frederick Can-
er Research Institute (Frederick, MD). BCNU was obtained from
he Drug Synthesis and Chemistry Branch of the National Cancer
nstitute (NCI; Bethesda, MD). The in vitro drug treatment incuba-
ions were carried out in serum free media at 37 ◦C as previously
escribed (Roth et al., 2012). Brieﬂy, cells were pretreated with
G for 1 h, then BCNU for 2 h. K562 cells were treated in Iscove’s
edia and then allowed to expand for 7 d. For in vitro selections,
urine BMCs or LSK cells were treated with 25 M BG and 0, 5,
5, or 25 M BCNU in alpha-MEM containing 1.2% spleen cell con-
itioned media (Stem Cell Technologies, Vancouver, BC, Canada).
rug treated murine BMCs or LSK cells were expanded in liquid
ulture using the same media formulation as described for trans-
uction without polybrene for 10 or 15 d, respectively. Progenitor
CFU) drug treatment survival assays were performed as previ-
usly described (Davis et al., 1997). For in vivo selection, three
ounds of selection, starting at 5 weeks post-transplant, were car-
ied out allowing 3 weeks recovery between each treatment. Each
ound, mice received i.p. injection with 30 mg/kg BG (dissolved to
 mg/mL  in 40% polyethylene glycol (Union Carbide Corp., Danbury,
T) and 60% PBS, pH 8.0), followed by i.p. injection of 10 mg/kg
CNU (dissolved in ethanol and diluted to 1 mg/mL  in PBS) an hour
ater.
.5. Flow cytometry
Flow cytometry data were acquired with an LSR ﬂow cytometer
Becton Dickinson, Franklin Lakes, NJ). GFP expression was mea-
ured in cells after a single wash in PBS. For MGMT  detection,
ells were ﬁxed in 2% paraformaldehyde for 30 min at 4 ◦C, per-
eablized in 1% Tween-20 for 30 or 60 min  (K562 or murine cells,
espectively) at 37 ◦C, and then blocked in 10% normal goat serum
t room temperature for 15 min. Cells were then incubated with
ouse anti-human MGMT  monoclonal antibody (clone MT3.1;
amiya Biomedical, Seattle, WA)  and an APC-conjugated goat anti-
ouse secondary antibody (Caltag Laboratories, Burlingame, CA).
ual detection of MGMT  and GFP expression was carried out with
he same staining protocol as that used for MGMT alone. Red
lood cells were lysed in murine PB and BM samples prior to
taining for ﬂow cytometry. Monoclonal antibodies against Gr-1,
D11b, B220, CD19, CD3, CD4, CD8, Ter119, Sca-1, and c-kit were
urchased from BioLegend (San Diego, CA) and BD Pharmingen
San Diego, CA).h 196 (2015) 170–180
2.6. Copy number analysis
The number of vector insertions per cell was evaluated using a
LightCycler instrument and the LightCycler FastStart DNA Master
SYBR Green I kit (Roche Diagnostics, Basel, Switzerland). MGMT
and GFP copy numbers were determined using proviral-speciﬁc
MGMT  and GFP primers, as described previously (Roth et al., 2012).
Genomic copy numbers were determined using GAPDL4-speciﬁc
primers, as previously described (Zielske et al., 2003). MGMT, GFP,
and GAPDL4 copy numbers were assessed using a standard curve
consisting of genomic DNA from murine PBLs spiked with known
MAG  vector copy numbers, and veriﬁed using K562 cell clones with
single MAG  vector insertion. One diploid copy of the mouse genome
was assumed to contain two copies of GAPDL4 and 5.9 pg of DNA.
MGMT,  GFP, and GAPDL4 copy numbers were analyzed in 8–15 CFU
per animal. The average number of vector insertions per marked
CFU in cotransduced cells is the cumulative average of the total
MGMT  and GFP copies, whereas the average number of vector inser-
tions per marked CFU in dual-gene vector transduced cells is the
combined average of the individual MGMT  and GFP copy numbers.
2.7. Cytospin and staining
At 72 h post-transduction, K562 cells were cytospun onto slides,
ﬁxed in 4% paraformaldehyde, and DAPI-stained (Vector Labora-
tories, Burlingame, CA) for nuclear visualization. GFP and DAPI
ﬂuorescence were visualized separately and the ﬂuorescent images
were superimposed using Image J software.
2.8. Western blotting
Following drug selection, K562 cells transduced with
pMND.MIG, pMND.MAG, pMND.GAH (not subjected to drug
selection), or cotransduced with pMND.GFP and pMND.MGMT,
were harvested and prepared for Western blotting as described
previously (Allay et al., 1995).
2.9. Statistical analysis
The data are shown as means ± s.d. or s.e.m. Analysis of variance
with Bonferroni’s post-test correction, for comparisons of three or
more groups, was used to assess statistical differences using Prism
4.0 (GraphPad Software, La Jolla, CA, USA). Statistical signiﬁcance
was accepted at P < 0.05.
3. Results
3.1. Dual-gene transfer strategies
Four self-inactivating lentiviral vectors were constructed: two
single-gene vectors containing MGMT-P140K (pMND-MGMT) or
enhanced GFP (pMND-GFP), and two dual-gene vectors contain-
ing either the EMCV-IRES (pMND-MIG) or FMDV-2A (pMND-MAG)
elements to allow co-expression of MGMT  and GFP (Fig. 1). The
MGMT-P140K gene was placed in the 5′ position of the dual-gene
vectors to ensure that the level of drug resistance gene expres-
sion was equal to that obtained with the MGMT  single-gene vector.
Equivalent levels of expression and drug resistance were veriﬁed in
K562 human erythroleukemia cells transduced with equal amounts
of MGMT,  MIG, or MAG  lentiviruses (Fig. 2).
3.2. Dual-gene transfer and in vitro enrichment of K562 cellsAs a ﬁrst approach to comparing cotransduction with single-
gene vectors to transduction with the MIG  and MAG  dual-gene
vectors, K562 cells were transduced using the same total MOI  for
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MND), central polypurine tract/central termination sequence (cPPT/CTS), as well as
′ restriction site was  used in the construction of each vector to ensure that all tran
ach method. The percentage of cells that expressed both MGMT
nd GFP (MGMT+GFP+) after cotransduction with pMND.MGMT
nd pMND.GFP (‘M + G’) was similar to that obtained with the dual-
ene MIG  vector (Fig. 3A). This similarity was observed for different
otal vector MOIs (1 or 5) for both sets of transductions and was
aintained after selection with 10 M BG and 25 M BCNU. Since
he total MOIs used for each transduction strategy were equiva-
ent (1 or 5), the MGMT  and GFP gene equivalents used for the
otransductions (0.5 each or 2.5 each, respectively) were a fraction
f those used in the dual-gene vector transductions. Nevertheless,
ncreased expression efﬁciency with the cotransduced vectors and
he reduced GFP expression obtained with the IRES-based vector
esulted in overall equivalent percentages of dual-gene expressing
ells with either strategy. Poor IRES-mediated translation efﬁciency
educed the percentage of dual-gene expressing cells detected (i.e.
ig. 2. MGMT  expression vectors confer equivalent protection from drug treatment.
562 cells were transduced (MOI = 0.5) with the MGMT  single-gene, MIG, or MAG
ual-gene vectors. At 72 h post-transduction the cultures were treated with 10 M
G and 0, 10, or 50 M BCNU and plated in methylcellulose for 10 d. Survival per-
entages are based on total colony-forming units (CFU), per number of cells plated,
ompared to untreated controls. Data are means ± s.e.m. of a representative exper-
ment with triplicate samples. *, P < 0.05; ns,  not signiﬁcant (P > 0.05). vectors used in this study. Each construct contains the MND  promoter/enhancer
oodchuck hepatitis virus post-transcriptional regulatory element (wPRE). The same
s have the same 5′-UTR sequences.
expression of MGMT  was consistently greater than GFP) (Fig. 3A).
In contrast, MGMT  and GFP were both efﬁciently expressed in K562
cells transduced with the dual-gene MAG  vector and resulted in the
highest percentage of dual-gene expressing cells in the untreated
and drug-treated cultures (Fig. 3A). Interestingly, the GFP  mean ﬂu-
orescence intensity (MFI) in MAG-transduced cells was 3–8 times
higher than in cotransduced or MIG-transduced cells, respectively
(Fig. 3B). Western blotting revealed that approximately half of the
MGMT  protein expressed from the dual-gene MAG  vector was
still fused to GFP (Fig. 3C), suggesting the 2A hydrolase activity is
not always effective (Chan et al., 2011). However, the presence of
fusion products did not affect the DNA repair activity (Fig. 2), as
previously reported for MGMT–GFP fusion constructs (Choi et al.,
2004). Furthermore, the majority of GFP signal in K562 cells trans-
duced with the MAG  dual-gene vector localized to the nucleus
(Supplementary Fig. S1), suggesting that most of the GFP signal
arises from MGMT–GFP fusions that are directed to the nucleus
via the nuclear localization signal (NLS) in MGMT.  MFI values for
GFP were much higher in cells transduced with the dual-gene MAG
vector, compared to cells transduced with the other dual-gene
delivery strategies, possibly due to nuclear localization. Alterna-
tively, MGMT-P140K has been shown to be incredibly stable with a
half-life of >18 h (Davis et al., 1999). Therefore, it is also possible that
the nuclear localized GFP fusion proteins resist degradation, or are
sequestered in the nucleus through DNA-binding activity of MGMT
binding activity, allowing the ﬂuorescent potential to accumulate.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.virusres.
2014.11.027.
3.3. Dual-gene transfer and in vitro enrichment of 5-FU-enriched
BMCs
As a ﬁrst approach to comparing these strategies in primary
cells, 5-FU-enriched murine BMCs were transduced using each
strategy. Higher MOIs were used to overcome the reduced trans-
duction efﬁciency of primary murine cell populations (Richard
et al., 2004; Visigalli et al., 2010; Pestina et al., 2009). Thus, BMC
174 J.C. Roth et al. / Virus Research 196 (2015) 170–180
A
B C
Fig. 3. Dual-gene transfer and expression in K562 cells. (A) Total MGMT+ or dual-positive (MGMT+GFP+) percentages obtained in K562 cells with each dual-gene transfer
strategy. Equivalent total vector MOIs (1 or 5) were used for each transduction strategy. Cotransduction with single-gene vectors (M+G) was carried out using equivalent
MGMT:GFP ratios (0.5:0.5 or 2.5:2.5). Transduced cultures were either mock treated (UT) or treated (T) with 10 M BG and 25 M BCNU and expanded in culture for 7 d prior
to  analysis. (B) Relative MFI  of MGMT  and GFP (measured separately) in cells from (A) after expansion in culture for 72 h. (C) Western blot of GFP (top) and MGMT (bottom)
in  protein extracts obtained from the drug-selected cultures in (A) (MOI = 1). The last lane in each blot is a control (K562 cells transduced with pMND-GFP-2A-HoxB4 not
undergoing drug selection) demonstrating a lack of fusion product with a separate dual-gene vector with an identical 2A linker sequence. MGMT  (M), GFP (G), MGMT with
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ultures were transduced with a total vector MOI  of 20. Although
he total MOI  was held constant for each experiment, equivalent
10:10) or staggered (5:15) MGMT:GFP vector MOI  ratios were used
or cotransductions with the single-gene vectors. The total MGMT
nd dual-gene expression percentages in the cotransduced BMC
ultures were lower, due to the lower MGMT  vector MOIs used,
nd the interdependence of the individual MGMT and GFP vector
ransduction rates (Fig. 4A). Cotransduction with equal MGMT  and
FP vector MOI  ratios resulted in slightly higher percentages of
ual-gene expressing cells compared to cotransduction with stag-
ered MGMT:GFP vector MOI  ratios (27% and 20%, respectively).
owever, 10 d after selection with 20 M BG and 25 M BCNU,
he percentages of dual-gene expressing cells were highest in cul-
ures cotransduced with the staggered (5:15) MGMT:GFP vector
OI  ratios (67%) due to the greater selection pressure. This was sim-
lar to the dual-gene expression percentages observed in cultures
ransduced with the dual-gene MIG  vector after drug treatment and
ulture expansion (62%). The same drug doses resulted in moder-
te enrichment of MGMT-expressing cells in cultures transduced
ith the dual-gene vectors (i.e. MIG  or MAG) since these cultures
ad higher initial MGMT  expression percentages (i.e. higher initial
ransduction resulted in less selection pressure).
The initially low MGMT  expression percentages in the cotrans-
uced cultures resulted in fewer BM progenitor CFU surviving drughe black arrowheads. Data in (A) are means ± s.e.m. of a representative experiment
; ##, P > 0.05 compared to M + G. Data in (B) are means ± s.e.m. of a representative
treatment, compared to cultures transduced with the dual-gene
vectors (Fig. 4B). Nevertheless, dual-gene expressing cells enriched
from the single-gene vector cotransduction cultures expressed
both genes at high levels (Fig. 4C). Equivalent MGMT  expression
levels were obtained in all the BMC  cultures after drug treat-
ment, but GFP expression levels in each cohort were signiﬁcantly
different (MAG > cotransduction > MIG; Fig. 4C). As in K562 cells,
the GFP ﬂuorescent intensities in BMCs transduced with the MAG
dual-gene vector were signiﬁcantly higher (Fig. 4C), possibly due to
nuclear localization of MGMT–GFP fusion products. The level of GFP
expression in single-gene vector cotransduced cells was  50% higher
than in cells transduced with the MIG  dual-gene vector. Thus, in
primary hematopoietic cells, cotransduction is limited by lower
initial dual-gene expression percentages, while IRES vectors yield
poor second gene expression levels, and 2A vectors are potentially
limited by inefﬁcient protein processing.
3.4. Dual-gene transfer and in vitro enrichment of LSK cells
Transduction efﬁciencies are reduced in more primitive
hematopoietic cell populations. To determine whether the
dual-gene expression percentages and the GFP expression levels
differed in more primitive populations, similar comparisons were
carried out on Lin–Sca-1+c-kit+ (LSK) cells. LSK cell cultures were
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Fig. 4. Dual-gene transfer and expression in 5-FU-enriched murine BMCs. (A) Total MGMT+ or dual-positive (MGMT+GFP+) percentages obtained in BMCs with each dual-gene
transfer  strategy. Equivalent total vector MOIs of 20 were used for each strategy. Cotransductions were carried out using MGMT:GFP MOI  ratios that were equivalent (10:10)
or  staggered (5:15). Transduced cultures were mock treated (UT) or treated (T) with 20 M BG and 25 M BCNU, and expanded in culture for 10 d prior to analysis. (B) CFU
survival  percentages in transduced BMC  cultures following treatment with 20 M BG and 0, 10, or 25 M BCNU. (C) Relative MFI  of MGMT  or GFP  expression in cells from
( resen
( ,  not s
t
i
2
v
(
t
t
i
m
o
f
i
L
L
d
t
M
h
a
c
v
(
t
p
t
cA)  after expansion in culture for 10 d. Data in (B) and (C) are means ± s.e.m. of a rep
10:10), M + G (5:15), and MIG; ##, P > 0.05 compared to all other MGMT  groups; ns
ransduced with each strategy using a total MOI  of 100, which
s typical for murine HSC transduction studies (Richard et al.,
004; Roth et al., 2012; Visigalli et al., 2010). However, the total
ector MOI  was again divided into equal (50:50) or staggered
20:80) MGMT:GFP vector MOI  mixtures for cotransduction with
he single-gene vectors. The initial GFP expression percentages in
he single-gene vector cotransduced LSK cultures had a greater
mpact on the dual-gene expression percentages after drug treat-
ent than MGMT  expression percentages, since limiting numbers
f drug resistance cells were efﬁciently enriched (Fig. 5A). There-
ore, the staggered MGMT:GFP vector MOI  ratio was further skewed
n favor of GFP expression in the single-gene vector cotransduced
SK cells. As an indicator of the overall lower transduction rate of
SK cells, the 5-fold higher dual-gene vector MOIs used to trans-
uce LSK cells resulted in dual-gene expressing cell percentages
hat were similar to those obtained in BMCs transduced with lower
OIs (Figs. 4A and 5A).
Transduction with the dual-gene MAG  vector resulted in the
ighest percentage of dual-gene expressing cells, in both untreated
nd drug treated cultures. After drug treatment, the highest per-
entage of dual-gene expressing cells among the single-gene
ector cotransduction cultures was obtained using the staggered
20:80) MGMT:GFP vector MOI  mixture, which was likely due to
he greater selection pressure (Fig. 5A). However, a slightly higher
ercentage of dual-gene expressing cells was obtained in cultures
ransduced with the dual-gene MIG  vector after drug selection,
ompared to the maximum achieved with cotransduction (86%tative experiment with triplicate samples. *, P < 0.05; #, P < 0.05 compared to M + G
igniﬁcant (P > 0.05).
and 73%, respectively). Since independent transduction events are
required for cotransduction, the reduced transduction efﬁciency
of LSK cells likely affected cotransduction to a greater extent than
that in the dual-gene vector transduced cultures.
MGMT  expression percentages correlated with drug resistant
CFU survival in each of the transduced LSK cultures (Fig. 5A and B).
As expected, the percentage of drug-resistant CFU in MIG  and MAG
transduced cultures were equivalent at both BCNU doses evaluated,
while CFU survival rates in cotransduced cultures were proportion-
ately lower, since these cultures were exposed to lower MOIs of
MGMT  and were subjected to greater selective pressure (Fig. 5B).
Nevertheless, this greater degree of selective pressure favored gene
expression, as post drug-selected liquid cultures of cotransduced
progenitors expressed GFP at levels twice as high as those trans-
duced with the dual-gene MIG  vector (Fig. 5C).
3.5. Enrichment of dual-gene expressing HSCs in vivo
To evaluate dual-gene expression efﬁciencies over a longer time
frame and more robust expansion conditions, we next compared
each strategy in vivo. Donor LSK cell populations were transduced
using a total MOI  of 100 for each strategy. The staggered (20:80)
MGMT:GFP vector MOI  ratio was used for cotransduction, based
on the superior dual-gene expression obtained with this ratio in
LSK cultures treated in vitro. Lethally irradiated recipients were
transplanted with 103 LSK cells from each transduction culture and
2 × 106 lineage-positive (Lin+) BMCs for hematopoietic support. At
176 J.C. Roth et al. / Virus Research 196 (2015) 170–180
A B
C
Fig. 5. Dual-gene transfer and expression in LSK-enriched murine BMCs. (A) Total MGMT+ or dual-positive (MGMT+GFP+) LSK cells obtained with each dual-gene transfer
strategy. Equivalent total MOIs of 100 were used for each strategy. Cotransductions were carried out using MGMT:GFP MOI  ratios that were equivalent (50:50) or staggered
(20:80).  Transduced cultures were mock treated (UT) or treated (T) with 20 M BG and 25 M BCNU, and expanded in culture 10 d prior to analysis. (B) CFU survival
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tercentages in transduced LSK cultures following treatment with 20 M BG and 0, 1
xpansion in culture for 15 d. Data in (B) and (C) are means ± s.e.m. of a representat
 + G (20:80), and MIG; ##, P > 0.05 compared to all other MGMT  groups; ns,  not si
 weeks post-transplant the mice were mock treated or treated
ith three rounds of 30 mg/kg BG and 10 mg/kg BCNU, allowing
 weeks recovery between each treatment. MGMT+ and GFP+ per-
entages were measured separately in peripheral blood leukocytes
PBL) 1 d prior to each treatment. MGMT  and GFP measurements
ere carried out individually due to loss of GFP ﬂuorescence inten-
ity in primary cells when staining for MGMT  (intranuclear), which
ade it difﬁcult to resolve single and dual-gene expressing cell
opulations. Therefore, total GFP or total MGMT expression per-
entages are reported.
At 5 weeks post-transplant (before drug selection), the per-
entage of MGMT+ PBL were equivalent (5 ± 4%) in each of the
hree cohorts (Fig. 6A). GFP+ PBL percentages in cotransduced and
AG-transduced cell recipients were similar (14 ± 5% and 13 ± 4%,
espectively), while MIG-transduced cell recipients had a lower
ercentage of GFP+ cells (5 ± 3%). After drug treatment and recov-
ry (16 weeks post-transplant), the average MGMT+ and GFP+ PBL
ercentages were enriched to a similar degree in each cohort; the
verage MGMT+ PBL percentage in cotransduced recipient ani-
als increased 11-fold (from 5 ± 3% to 58 ± 22%), compared to
-fold increases (from 5 ± 4% to 37 ± 24%) in MIG-transduced cell
ecipients, and 9-fold increases (from 5 ± 2% to 47 ± 17%) in MAG-
ransduced cell recipients (Fig. 6A). Average GFP+ PBL percentages
ncreased by 7-fold (from 5 ± 3% to 34 ± 18%) in MIG-transduced
ell recipients and by 5-fold (from 13 ± 4% to 65 ± 15%) in MAG-
ransduced cell recipients. Enrichment for GFP+ cells was lower in
he cohort cotransduced with the single-gene vectors (3-fold; from5 M BCNU. (C) Relative MFI  of MGMT  or GFP expression in LSK cells from (A) after
periment with triplicate samples. *, P < 0.05; #, P < 0.05 compared to M + G (50:50),
nt (P > 0.05).
14 ± 5% to 39 ± 8%) due to expansion of MGMT  singly-transduced
cells and loss of the drug sensitive GFP singly-transduced cells
(Fig. 6A). One animal in the MIG-transduced cohort had to be eutha-
nized after the third treatment. MGMT+ PBLs in this animal declined
after the ﬁrst and second treatments, indicating a lack of engraft-
ment with drug-resistant cells. Mock treated animals in all three
transduction cohorts did not show enrichment of either MGMT+ or
GFP+ PBLs at 16 weeks post-transplant (p > 0.05).
At 17 weeks post-transplant, the animals were sacriﬁced and
BMCs were harvested. At this point, stable hematopoiesis post-drug
selection allowed analysis of progenitor selection, as impacted by
the different transduction strategies. Drug selection increased the
proportion of gene-expressing cells (Fig. 6B). MGMT+ BMC  per-
centages in cotransduced cell recipient animals increased from
0 to 14% in the untreated controls to an average of 77 ± 27% in
the drug treated animals. In the same cohort, GFP+ BMC  percent-
ages increased from 5 ± 4% in untreated animals, to 61 ± 29% in
the drug treated animals (Fig. 6B). Among the dual-gene vector
cohorts, the average MGMT+ and GFP+ BMC  percentages in MIG-
transduced recipients were not signiﬁcantly different between
drug treated and untreated control animals (p > 0.05) since one
of the untreated animals engrafted with a high percentage of
dual-gene expressing cells in the absence of selection (see Sup-
plementary Fig. S2 for individual mouse data). In contrast, among
the MAG-transduced cell recipients, MGMT+ BMC  percentages
increased from 4 ± 2% in untreated controls to 84 ± 3% in the drug
treated animals. Likewise, GFP+ BMC  percentages increased from
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Fig. 6. Dual-gene transfer, selection, and expression in vivo. Three different cohorts of mice (n = 7–9 animals per cohort) were transplanted with cotransduced (M + G),
MIG-transduced, or MAG-transduced LSK cells. (A) Total MGMT+ and GFP+ percentages in murine PBLs at 5 and 16 weeks after transplant. At 5 weeks post-transplant animals
were  mock treated or selected with 3 rounds of 30 mg/kg BG and 10 mg/kg BCNU, with 3 weeks between each round of selection. Values at 5 weeks are the expression
percentages prior to the ﬁrst treatment. Values depicted at 16 weeks are expression percentages in mock treated (UT; n = 2 animals per transduction cohort) or thrice-treated
(T;  n = 5–7 animals per transduction cohort) animals. (B–E) Recipient animals in A were sacriﬁced at 17 weeks post-transplant for BMC  analysis. (B) Total MGMT+ and GFP+
expression percentages in total BMCs. (C) Total GFP+ expression percentages in lymphoid (B220+) and granulocytic (Gr-1+) BMCs. (D) Relative MFI  of MGMT  or GFP expression
(measured separately) in BMCs. (E) The average number of vector insertions per cell, calculated from individual CFU. Values were determined using primers for either MGMT
or  GFP on individual CFU (n = 8–15 CFU per animal). Mean MGMT  and GFP values were calculated from all of the CFU analyzed in each animal. Mean MGMT  and GFP values
were  totalled (cotransduced CFU), or averaged (MIG and MAG  transduced CFU) to get the total number of vector insertion per cell. For individual animal data, please see
Supplementary Fig. S2. Data in A are means ± s.e.m. *, P < 0.05 compared to 5 wks  UT; **, P < 0.05 compared to 5 or 16 wks UT; #, P < 0.05 for MAG  compared to either M + G
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ir  MIG; ##, P > 0.05 for MAG  compared to either M + G or MIG; ns,  not signiﬁcant (P
ompared to either M + G or MIG; ##, P > 0.05 for MAG  compared to either M + G or
 ± 2% to 79 ± 18% after drug treatment. Furthermore, multilineage
election was observed in each of the three drug treated animal
ohorts, with increased GFP expression in B220+ and Gr-1+ BMC
ractions (Fig. 6C). As with the in vitro experiments, the level of
GMT  expressed in the MGMT+ BMCs was not signiﬁcantly dif-
erent among the cohorts, while the GFP expression levels were
Fig. 6D). As expected, GFP expression was localized to the nuclei
f MAG-transduced cells (data not shown), which may  artiﬁcially
nﬂate MFI-based assessment of GFP expression levels. Interest-
ngly, the GFP expression levels in cotransduced recipient BMCs). Data in B–E are means ± s.e.m. *, P < 0.05 (T compared to UT); #, P < 0.05 for MAG
ns,  not signiﬁcant (P > 0.05).
was over 3-fold higher than that in cells transduced with the MIG
vector.
3.6. Enrichment of transduced HSCs does not increase copy
numberReal-time PCR analysis was  then used to determine the num-
ber of total vector insertions per cell in individual CFU recovered
from each cohort (Fig. 6E). While the proportion of transduced CFU
increased after drug treatment, the average number of insertions
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n marked CFU was not signiﬁcantly different among the dif-
erent cohorts of drug treated animals (P > 0.05). In drug-treated
nimals, the number of vector insertions per marked cell aver-
ged 5 ± 3 (range 1.7 ± 0.2 to 10 ± 1) in cotransduced recipients,
ompared to 6 ± 5 (range 1.3 ± 0.5 to 14.1 ± 0.1) and 4 ± 1 (range
.6 ± 0.1 to 6 ± 1) in MIG-transduced and MAG-transduced recipi-
nts, respectively. These data indicate that selection does not skew
oward cells containing high copy numbers and, compared to dual-
ene vector strategies, cotransduction with separate single-gene
ectors does not result in an overall increase in vector inser-
ions.
Numerical expansion levels were then estimated based on the
ngrafted cell transduction and expression efﬁciencies, as well as
he total cellular reconstitution levels. On this basis, and assum-
ng the normal mouse bone marrow compartment consists of
3 × 108 BMCs (Boggs, 1984; Reese et al., 2001), dual-gene express-
ng cells in cotransduced recipient animals were enriched by an
verage of 1.8 ± 0.5 × 107-fold, compared to 1.8 ± 0.9 × 107-fold
n MIG-transduced recipients and 1.18 ± 0.08 × 106-fold in MAG-
ransduced recipients. Additionally, studies by Colvin et al. (2004)
uggest the bone marrow compartment is comprised of closer
o 4.7 × 108 BMCs, which would result in further gains (∼155%
ncrease) in the enrichment of dual-gene expressing cells. The
ower level of MAG-transduced cell expansion was  due to the
ower selection pressure exerted on initially greater numbers of
ual-gene expressing cells in the transduced donor cell popu-
ations. Thus, the overall level of dual-positive cell enrichment
n the cotransduced and MIG-transduced recipients was  equiva-
ent.
These data indicate that similar levels of vector insertions are
btained with each strategy before and after drug selection. In addi-
ion, despite initially lower levels of MGMT+ cells, the cotransduced
opulations still contained sufﬁcient numbers for engraftment and
ultilineage repopulation with cells expressing high levels of both.
hus, cotransduction with single-gene vectors may  be an efﬁcient
lternative to dual-gene vectors for coupling hematopoietic pro-
enitor selection to therapeutic gene expression, particularly as a
rst approach to establishing feasibility.
. Discussion
Studies aimed at coupling selective stem cell enrichment to
herapeutic gene expression have focused on the use of dual-gene
ectors (Persons et al., 2003; Falahati et al., 2012; Richard et al.,
004; Trobridge et al., 2009). Many strategies have been employed
o co-express two genes from the same vector, including the use of
lternative splice sites, internal promoters, gene fusions, IRES ele-
ents, and ribosome slippage sites (Morgan et al., 1992; Sugimoto
t al., 1994; de Felipe et al., 1999; Klump et al., 2001). However,
igher MOIs are often needed for dual-gene vectors to compen-
ate for low expression levels. Recently, we demonstrated that
otransduction, coupled with MGMT-mediated selection, allows
nrichment of dual-positive cells in vivo (Roth et al., 2012). In the
resent study we aimed to directly compare cotransduction with
ingle-gene vectors to transduction with dual-gene vectors in the
ontext of MGMT-mediated hematopoietic progenitor cell enrich-
ent. The work reported herein supports our previous work in
hat MGMT-mediated selection can be used to efﬁciently enrich
ematopoietic progenitor cells cotransduced with separate single-
ene lentivectors. Although the initial dual-gene transfer rates
re reduced with this strategy, the percentage of dual-expressing
ells that are enriched after drug selection are similar to per-
entages obtained after transduction with dual-gene vectors. In
ddition, the populations cotransduced with the single-gene vec-
ors expressed both gene products at high levels with vectorh 196 (2015) 170–180
insertion averages equivalent to those obtained with dual-gene
vectors.
Advantages and disadvantages exist for each dual-gene vec-
tor strategy that are speciﬁc to the particular application or gene
combinations used. Strong selective pressure applied to alterna-
tive splicing or internal promoter strategies can lead to preferential
splice site recognition or promoter interference, favoring drug
resistance gene expression at the cost of therapeutic gene expres-
sion (Emerman and Temin, 1984). Gene fusion is likely the most
efﬁcient strategy, but requires that both gene products are func-
tional as a fusion and active in the same cellular compartment.
Previously, Amendola et al. (2005) reported the creation of dual-
gene lentivectors using bidirectional promoters. These promoters
co-express two  genes that are positioned in opposite orientations
to one another in the same vector. However, the efﬁciency of this
strategy in the setting of stringent drug selection remains to be
determined.
The most common dual-gene expression strategies utilize IRES
or ribosome slippage sequences for co-expression. Therefore, we
compared cotransduction of single-gene MGMT  and GFP vectors
to dual-gene vectors that utilized IRES or 2A ribosome slippage
sites to co-express MGMT  and GFP. The EMCV IRES and FMDV-
2A elements were speciﬁcally chosen, since these sequences have
been thoroughly characterized and are routinely used in dual-gene
expression vectors. The dual-gene MIG  vector used in these studies
was constructed to maximize IRES-mediated GFP expression. IRES
activity has been reported to be most efﬁcient when the IRES is
placed less than 100 nucleotides downstream of the ﬁrst gene (Attal
et al., 1999). Therefore, the IRES in the dual-gene MIG  vector was
inserted 70 nucleotides downstream of MGMT.  The position of the
second gene’s start codon with respect to the EMCV-IRES sequence
is also critical, since a speciﬁc AUG site is preferentially used for
IRES-initiated translation (Davies and Kaufman, 1992). Thus, GFP
was cloned into an NcoI site engineered to position the GFP start
codon at the optimal site for IRES-initiated translation. Although
the same genes had to be maintained for a comparative study,
cis-acting complications have also been attributed to the speciﬁc
genes used in bicistronic constructs (Hennecke et al., 2001). In the
studies reported here, MIG-transduced cells efﬁciently expressed
MGMT,  but the GFP expression levels were 2 to 3-fold lower than
levels obtained in cells cotransduced with the single-gene vec-
tors, despite similar vector insertion averages. Low IRES-mediated
translation efﬁciencies have been reported using similar gene com-
binations (i.e. MGMT  and GFP) (Chinnasamy et al., 2006) as well as
other gene combinations, and IRES elements (Hennecke et al., 2001;
Chan et al., 2011; Ibrahimi et al., 2009). IRES-mediated expression
appears to be particularly low in lentiviral vectors. This may  be due
to the lower transcription rates obtained with internal lentivector
promoters, compared to LTR-mediated transcription in retroviral
vectors.
The FMDV-2A element has also been thoroughly character-
ized and successfully used in multi-gene vectors (de Felipe et al.,
1999; Milsom et al., 2004; Chan et al., 2011; Lengler et al., 2005;
Chinnasamy et al., 2006; Furler et al., 2001; Ryan and Drew, 1994;
Kim et al., 2011; Szymczak et al., 2004). The 2A consensus sequence
has been used in our lab to co-express other gene combinations.
While, the C-terminal 2A fusion residues perturbed gene func-
tion in one such construct, no evidence of fusion products were
previously detected. Similar complications have been reported in
the literature by others. Lengler et al. (2005) found that the C-
terminal 2A residues speciﬁcally destabilized some gene products
and not others. Milsom et al. (2004) and Chinnasamy et al. (2006)
reported the use of dual-gene vectors, containing an MGMT-2A-
GFP cassette similar to that of the dual-gene MAG  vector reported
here. Although slightly different linker sequences may  have been
used, similar levels of MGMT–GFP fusion products were reported.
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hus, the efﬁciency of 2A processing appears to be more related
o the speciﬁc gene combinations (Chan et al., 2011) or length of
he 2A element (Donnelly et al., 2001; Minskaia and Ryan, 2013)
sed, rather than a cell type-speciﬁc phenomenon. Furthermore,
ther 2A sequence elements in addition to the FMDV-2A have been
dentiﬁed and evaluated in various systems, with data indicating
hat 2A processing efﬁciency also varies among these different ele-
ents (Kim et al., 2011). Nevertheless, despite that as much as half
f detected MGMT  protein in MAG  transduced cells was  actually
ncleaved MGMT-2A-GFP, MGMT  repair activity was  unaffected
y this fusion with GFP. In this regard, the most efﬁcient dual gene
xpression strategy in the studies reported here was  achieved with
he dual-gene MAG  vector, similar to others (Chinnasamy et al.,
006).
The selection stringency imparted through the BG + BCNU selec-
ion strategy used in this report impacts the level of enrichment
hich is primarily dependent on the level of MGMT expressed. In
ur hands there appears to be a threshold MOI required to efﬁ-
iently transduce LSK cells, as determined by expression-based
eadouts. However, even limiting amounts of MGMT  affords pro-
ection, but multiple insertions may  be required to achieve even
imiting expression. Nevertheless, we have previously demon-
trated that more stringent selection does not necessarily translate
o increased copy numbers (Zielske et al., 2004). Unlike the dual-
ene vector strategies, which were limited by lower expression
evels or inefﬁcient processing, cells cotransduced with the single-
ene vectors expressed both genes at high levels. Cotransduction
s limited by the reduced dual-gene transfer rates inherent to this
trategy. However, MGMT-mediated selection sufﬁciently enriched
imiting numbers of cotransduced progenitor cells. Lower MGMT
ene equivalents were used in cotransduction experiments to keep
he total MOIs equivalent. This led to lower initial percentages of
rug-resistant cells, compared to the percentages obtained with
he dual-gene vectors. However, after selection the percentage
f MGMT+ cells in the cotransduced cultures were equivalent to
he percentages obtained with the dual-gene vectors. Thus, the
evel of expansion did not appear to be a limiting factor for cells
otransduced with the single-gene vectors. The initial proportion
f dual-expressing cells to MGMT-singly transduced cells deter-
ined the dual-expressing cell percentage after selection. While
he cotransduction studies reported here relied on the individ-
al vector transduction rates, strategies that physically couple the
eparate vectors should improve the efﬁciency of cotransduction.
hang et al. (2001) reported that low molecular weight polylysine
olymers allow low-speed concentration of VSVG-pseudotyped
entivectors. The virus-polylysine precipitates in these studies
esembled “beads on a string.” Thus, a similar strategy might be
sed to co-precipitate separate viruses used for cotransduction,
sing vector MOI  ratios that are optimized for each application.
. Conclusions
These studies demonstrate that cotransduction with single-
ene vectors is an efﬁcient alternative to dual-gene vectors for
elective expansion of dual-gene expressing hematopoietic pro-
enitor cells in vivo. Although higher levels of expansion are
equired with this strategy, MGMT-mediated enrichment was  not
imiting. Further, the single-gene vectors were less prone to the
is-acting complications in the dual-gene vectors that reduced
rotein expression or processing. Since the degree of selective
xpansion and expression obtained using the single-gene MGMT
ector is independent from that of another cotransduced vector,
reviously-established MGMT  vector MOIs and drug-selection con-
itions could be applied to a wide range of therapeutic vectors
s a ﬁrst approach to establishing feasibility in HSC gene therapy
odels.h 196 (2015) 170–180 179
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